Investment Highlights

Strong position in the field of bladder cancer with solid growth plans and ambition to expand footprint.

Commercial-stage company focused on bladder cancer

Hexvix®/Cysview® for improved detection of bladder cancer, reduced disease recurrence and progression rates with cost benefits:

  • USD 30M global in market sales.
  • Specialist salesforce established in the US and Nordic region and additional emerging operations in other high-value territories through our partners Ipsen (EU), Juno Pharmaceuticals (Australia/New Zealand), and BioSyent Pharma (Canada).

Value-building opportunities towards 2020

  • Large untapped potential for Hexvix®/Cysview® in existing and new market segments/territories.
  • FDA approval of Cysview® for use with flexible cystoscope.
  • Clarity on reimbursement for Cysview® in the US.
  • Exploring expansion of bladder cancer portfolio to leverage commercial infrastructure.
  • Partnering opportunities for non-urology assets: Cevira® (cervical disease) and Visonac® (acne).